Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease

Experimental Neurology

Volumn 166, Issue 1, 2000, Pages 29-43

  Tatton, Nadine A ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Apoptosis; Bax; Caspase 3; GAPDH; Mitochondria; Nuclear; Parkinson's disease; TUNEL

Indexed keywords

CASPASE 3; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PROTEIN BAX;

APOPTOSIS; ARTICLE; CHROMATIN CONDENSATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEWY BODY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0033756901     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7489     Document Type: Article

References (69)

1. P53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors
2. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
3. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging
4. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
5. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
6. Post-mortem stability of DNA
7. Bax, but not Bcl-xL, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations
8. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain
9. Reduced apoptosis after NGF and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase
10. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
11. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: Evidence that GAPDH is upregulated by p53
12. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation
13. Human mitochondrial complex I dysfunction
14. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons
15. Measurement of apoptosis
16. Biochemical properties of purified human terminal deoxynucleotidyltransferase
17. Mitochondrial DNA and Parkinson's disease
18. Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis
19. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
20. General pathology of neurons and neuroglia
21. Different pro-oxidant levels stimulate growth, trigger apoptosis or produce necrosis of insulin-secreting RINmSF cells: The role of intracellular polyamines
22. Specific in situ end labeling of apoptosis shows different rates of programmed cell death in non-Hodgkin lymphomas
23. Identification of programmed cell death in-situ via specific labeling of nuclear DNA fragmentation
24. CD95 (APO-1/Fas) and Parkinson's disease
25. Glyceraldehyde phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytotoxic arabinonucleoside-induced apoptosis in cultured cerebellar neurons
26. Overexpression of glyceraldehyde-3-phosphate dehydrogenase is involved in low K+-induced apoptosis but not necrosis of cultured cerebellar granule cells
27. Nuclear localization of overexpressed glyceral-dehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis
28. Chromatin condensation during apoptosis requires ATP
29. Apoptosis, a basic biological phenomenon with wide-ranging implications I in tissue kinetics
30. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect?
31. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
32. On the question of apoptosis in the parkinsonian substantia nigra
33. Mitochondrial NADH dehydrogenase and CYP2D6 in Lewy-body parkinsonism
34. Distinction of apoptotic and necrotic cell death by in situ labelling of fragmented DNA
35. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
36. DNA damage distribution in the human brain as shown by in situ end labeling: Area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology
37. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis
38. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks
39. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
40. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease
41. Histochemical detection of apoptosis in Parkinson's disease
42. The soluble form of Fas molecule is elevated in parkinsonian brain tissues
43. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease
44. Biddable death
45. Caspase structure, proteolytic substrates, and function during apoptotic cell death
46. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation
47. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis programmed cell death
48. Effect of postmortem interval on in situ end-labeling of DNA oligonucleosomes
49. A model for p53-induced apoptosis
50. Axotomy-induced apoptotic cell death of neonatal rat facial motoneurons: Time course analysis and relation to NADPH-diaphorase activity
51. Acinus is a caspase 3-activated protein required for apoptotic chromatin condensation
52. Glyceraldehyde-3-phosphate dehydrogenase: Nuclear translocation participates in neuronal and nonneuronal cell death
53. Mitochondrial complex I deficiency in Parkinson's disease
54. Mitochondrial involvement in Parkinson's disease. Huntington's disease, hereditary spastic paraplegia and Freidrich's ataxia
55. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c
56. Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology
57. The central executioner of apoptosis: Multiple links between protease activation and mitochondria in Fas/Apo-1/CD95- and ceramide-induced apoptosis
58. Enzymatic manipulation of DNA and RNA
59. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
60. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
61. Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's disease
62. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
63. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
64. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
65. Evidence that DNA fragmentation in apoptosis is initiated and propogated by single-strand breaks
66. Endenuclease activities, chromatin structure, and DNA degradation in apoptosis
67. Movement of Bax from the cytosol to mitochondria during apoptosis
68. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
69. Bax involvement in p53-mediated neuronal cell death